What is the recommended dosage of Paxlovid (nirmatrelvir and ritonavir) for the treatment of COVID-19 in adults with underlying medical conditions or impaired renal function?

Paxlovid Dosage for COVID-19 Treatment

The standard dosage of Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), taken together twice daily for 5 days, with dose reduction required for moderate-to-severe renal impairment. 1

Standard Dosing Regimen

• Initiate treatment as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 1, 2
• Administer all 3 tablets together twice daily at approximately the same time each day 1
• Can be taken with or without food 1
• Complete the full 5-day course 1

Dose Adjustments for Renal Impairment

Moderate Renal Impairment (eGFR 30-59 mL/min):

• Reduce to 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) twice daily for all 5 days 1, 2

Severe Renal Impairment (eGFR <30 mL/min), Including Hemodialysis:

• Day 1: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) once daily 1
• Days 2-5: 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) once daily 1
• On hemodialysis days, administer the dose after hemodialysis 1

The rationale for these reductions is that nirmatrelvir exposure increases substantially with declining renal function—by 87% in moderate impairment and 204% in severe impairment compared to normal function 1. The adjusted dosing regimen in severe renal impairment achieves comparable exposures to standard dosing in patients with normal renal function 1.

Hepatic Impairment Considerations

• No dose adjustment needed for mild-to-moderate hepatic impairment (Child-Pugh Class A or B) 1
• Paxlovid is NOT recommended in severe hepatic impairment (Child-Pugh Class C) as this population has not been studied 1, 2

Critical Drug Interaction Management

Before prescribing Paxlovid, you must systematically check for drug-drug interactions using the Liverpool COVID-19 Drug Interaction Tool, as ritonavir is a potent CYP3A4 inhibitor that causes potentially life-threatening interactions 2, 1. Ritonavir causes interactions during active treatment and for several days after completion 2.

Contraindicated medications include those highly dependent on CYP3A for clearance where elevated concentrations cause serious or life-threatening reactions 1. Common examples requiring dose adjustment or temporary discontinuation include:

• Statins (particularly simvastatin and lovastatin—consider temporary discontinuation) 2
• Anticoagulants like apixaban (reduce dose by 50% during treatment) 3
• Immunosuppressants 2
• Certain antiarrhythmics 1

Monitoring Requirements

Reassess renal function during treatment if clinical deterioration occurs, as COVID-19 itself can cause acute kidney injury, which would further increase nirmatrelvir levels 2, 3. Monitor for:

• Common adverse effects: dysgeusia (altered taste) and diarrhea, which occur more frequently than placebo but rarely require discontinuation 2
• Signs of hypersensitivity reactions including anaphylaxis, which require immediate discontinuation 1
• Hepatotoxicity: monitor liver enzymes if clinically indicated 1

Special Population Considerations

Pediatric patients (12 to <18 years) weighing ≥40 kg: Use the standard adult dose of 300 mg/100 mg twice daily 4

Pregnant patients: Paxlovid may be used to reduce disease progression, though data are limited; discuss potential benefits versus risks 2

Patients with uncontrolled HIV: Be aware that Paxlovid use may lead to HIV-1 protease inhibitor resistance 1

Common Pitfalls to Avoid

• Do not delay initiation due to anticoagulation concerns—the interaction is manageable with dose adjustment, and Paxlovid must be started within 5 days of symptom onset for effectiveness 3
• Do not treat the Liverpool interaction checker as optional—this is explicitly recommended in guidelines for systematic checking 2
• Do not continue renally-eliminated comedications at full dose without reassessing—advanced age combined with renally-eliminated drugs significantly increases risk of excessive plasma concentrations 5
• Do not prescribe for patients hospitalized primarily for non-COVID conditions who incidentally test positive—clinical judgment should guide whether treatment is appropriate 6